OBJECTIVES: We evaluated the effect of the time interval between the initiation of antiretroviral therapy (ART) and the initiation of tuberculosis (TB) treatment on clinical outcomes in HIV/TB-coinfected patients in an Asian regional cohort. METHODS: Adult HIV/TB-coinfected patients in an observational HIV-infected cohort database who had a known date of ART initiation and a history of TB treatment were eligible for study inclusion. The time interval between the initiation of ART and the initiation of TB treatment was categorized as follows: TB diagnosed while on ART, ART initiated ≤ 90 days after initiation of TB treatment ('early ART'), ART initiated > 90 days after initiation of TB treatment ('delayed ART'), and ART not started. Outcomes were assessed using survival analyses. RESULTS: A total of 768 HIV/TB-coinfected patients were included in this study. The median CD4 T-cell count at TB diagnosis was 100 [interquartile range (IQR) 40-208] cells/μL. Treatment outcomes were not significantly different between the groups with early ART and delayed ART initiation. Kaplan-Meier analysis indicated that mortality was highest for those diagnosed with TB while on ART (3.77 deaths per 100 person-years), and the prognoses of other groups were not different (in deaths per 100 person-years: 2.12 for early ART, 1.46 for delayed ART, and 2.94 for ART not started). In a multivariate model, the interval between ART initiation and TB therapy initiation did not significantly impact all-cause mortality. CONCLUSIONS: A negative impact of delayed ART in patients coinfected with TB was not observed in this observational cohort of moderately to severely immunosuppressed patients. The broader impact of earlier ART initiation in actual clinical practice should be monitored more closely.
OBJECTIVES: We evaluated the effect of the time interval between the initiation of antiretroviral therapy (ART) and the initiation of tuberculosis (TB) treatment on clinical outcomes in HIV/TB-coinfectedpatients in an Asian regional cohort. METHODS: Adult HIV/TB-coinfectedpatients in an observational HIV-infected cohort database who had a known date of ART initiation and a history of TB treatment were eligible for study inclusion. The time interval between the initiation of ART and the initiation of TB treatment was categorized as follows: TB diagnosed while on ART, ART initiated ≤ 90 days after initiation of TB treatment ('early ART'), ART initiated > 90 days after initiation of TB treatment ('delayed ART'), and ART not started. Outcomes were assessed using survival analyses. RESULTS: A total of 768 HIV/TB-coinfectedpatients were included in this study. The median CD4 T-cell count at TB diagnosis was 100 [interquartile range (IQR) 40-208] cells/μL. Treatment outcomes were not significantly different between the groups with early ART and delayed ART initiation. Kaplan-Meier analysis indicated that mortality was highest for those diagnosed with TB while on ART (3.77 deaths per 100 person-years), and the prognoses of other groups were not different (in deaths per 100 person-years: 2.12 for early ART, 1.46 for delayed ART, and 2.94 for ART not started). In a multivariate model, the interval between ART initiation and TB therapy initiation did not significantly impact all-cause mortality. CONCLUSIONS: A negative impact of delayed ART in patients coinfected with TB was not observed in this observational cohort of moderately to severely immunosuppressed patients. The broader impact of earlier ART initiation in actual clinical practice should be monitored more closely.
Authors: Enrico Girardi; Caroline A Sabin; Antonella d'Arminio Monforte; Bob Hogg; Andrew N Phillips; M John Gill; Francois Dabis; Peter Reiss; Ole Kirk; Enos Bernasconi; Sophie Grabar; Amy Justice; Schlomo Staszewski; Gerd Fätkenheuer; Jonathan A C Sterne Journal: Clin Infect Dis Date: 2005-11-11 Impact factor: 9.079
Authors: Jialun Zhou; N Kumarasamy; Rossana Ditangco; Adeeba Kamarulzaman; Christopher K C Lee; Patrick C K Li; Nicholas I Paton; Praphan Phanuphak; Sanjay Pujari; Asda Vibhagool; Wing-Wai Wong; Fujie Zhang; John Chuah; Kevin R Frost; David A Cooper; Matthew G Law Journal: J Acquir Immune Defic Syndr Date: 2005-02-01 Impact factor: 3.771
Authors: A Jiamsakul; E Yunihastuti; K Van Nguyen; T P Merati; C D Do; R Ditangco; S Ponnampalavanar; F Zhang; S Kiertiburanakul; M-P Lee; A Avihingasanon; O T Ng; B L Sim; W Wong; J Ross; M Law Journal: HIV Med Date: 2018-04-23 Impact factor: 3.180
Authors: A Jiamsakul; M-P Lee; K V Nguyen; T P Merati; D D Cuong; R Ditangco; E Yunihastuti; S Ponnampalavanar; F Zhang; S Kiertiburanakul; A Avihingasanon; O T Ng; B L H Sim; W-W Wong; J Ross; M Law Journal: Int J Tuberc Lung Dis Date: 2018-02-01 Impact factor: 2.373
Authors: William Worodria; Victor Ssempijja; Coleen Hanrahan; Richard Ssegonja; Abdallah Muhofwa; Doreen Mazapkwe; Harriet Mayanja-Kizza; Steven J Reynolds; Robert Colebunders; Yukari C Manabe Journal: AIDS Date: 2018-09-24 Impact factor: 4.177
Authors: Anna Odone; Silvia Amadasi; Richard G White; Theodore Cohen; Alison D Grant; Rein M G J Houben Journal: PLoS One Date: 2014-11-12 Impact factor: 3.240